Abstract:Objective: The aim was to study the impact of coronavirus disease 2019 (COVID-19) convalescence on female fertility and laboratory and clinical outcomes in fresh assisted reproductive technology (ART) cycles. Methods: In this retrospective cohort study, we analyzed data from 294 patients who had recovered from COVID-19 and who underwent fresh ART cycles between January and March 2023 (COVID-19 group). This group was compared with 631 patients who underwent similar ART cycles in the same period in 2022 but without having been infected with COVID-19 (non-COVID-19 group). The analysis focused on comparison of basic demographic characteristics and laboratory parameters of patients in each group. The primary outcome measure was the clinical pregnancy rate, which was examined to assess the impact of COVID-19 infection on the efficacy of ART treatment. Results: Basal follicle-stimulating hormone (FSH) levels were significantly lower and antral follicle count (AFC) was markedly higher in the COVID-19 group compared to the non-COVID-19 group (P<0.001 and P=0.004, respectively). The predominant ovarian stimulation protocol in the COVID-19 group was GnRH antagonists (64.85%, P<0.001), with a reduced gonadotropin (Gn) dosage and duration in comparison to the non-COVID-19 group (P<0.05). Although the number of blastocysts formed was lower in the COVID-19 group (P=0.017), this group also exhibited a higher blastocyst freezing rate and a higher rate of high-quality embryos per retrieved oocyte (P<0.001 and P=0.023, respectively). Binary logistic regression analysis indicated that COVID-19 convalescence did not significantly impact clinical pregnancy rates in fresh transfer cycles (odds ratio [OR] = 1.16, 95% confidence interval [CI] = 0.68-1.96, P=0.5874). However, smooth curve-fitting and threshold effect analysis revealed an age-related decline in clinical pregnancy rates in both groups, more pronounced in the COVID-19 group, for women aged over 38 years, with the likelihood of clinical pregnancy decreasing by 53% with each additional year of age (odds ratio [OR] = 0.81, 95% confidence interval [CI] = 0.61–1.08, P=0.1460; odds ratio [OR] = 0.47, 95% CI = 0.21–1.05, P=0.0647). Conclusions: Our findings present no substantial evidence of adverse effects on clinical pregnancy outcomes in fresh ART cycles in patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) during the period of convalescence from COVID-19. However, age emerges as a significant factor influencing these outcomes. Notably, for women above 38 years of age, the likelihood of clinical pregnancy in patients with a prior COVID-19 infection decreased by 53% with each additional year. This highlights the importance of considering maternal age, especially in the context of COVID-19, when evaluating the likelihood of successful pregnancy following ART treatments.

Impacts and Prompts of COVID-19 Outbreaking on Assisted Reproductive Technology Services in Beijing

Impact of COVID-19 pandemic on the pregnancy outcomes of women undergoing assisted reproductive techniques (ARTs): a systematic review and meta-analysis

Impacts of the COVID-19 pandemic on Chinese assisted reproductive technology institutions and human sperm banks: reflections in the post-pandemic era

A brief account of the assessment of the human assisted reproduction technology in China

Assisted Reproductive Technology in Beijing, 2013-2015.

The impact of coronavirus disease 2019 on frozen-thawed embryo transfer outcomes

Analysis of the vaccination of people treated with assisted reproductive technology

Effect of assisted reproductive technologies on health conditions of pregnant women and their babies

Assisted Reproductive Technology in China: Results Generated From Data Reporting System by CSRM From 2013 to 2016

Effects of SARS-CoV-2 infection on embryological outcomes in assisted reproductive technology during the Omicron epidemic

Maternal and Live-birth Outcomes of Pregnancies Following Assisted Reproductive Technology: A Retrospective Cohort Study

SARS-CoV-2 and Assisted Reproductive Technology Practice: an Asia Pacific Initiative on Reproduction (ASPIRE) Position Paper

Effect of SARS-CoV-2 vaccination on the outcomes of assisted reproductive technology: A review

Impact of the COVID-19 pandemic on sexual and reproductive health among women with induced abortion

Assisted Reproductive Technology in China: Compliance and Non-Compliance.

Impact Of Covid-19 Pandemic On The Clinical Activities In Obstetrics And Gynecology: A National Survey In China

COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management

Impact of COVID-19 convalescence on pregnancy outcomes in patients undergoing IVF/ICSI during fresh ART cycles: a retrospective cohort study

State of assisted reproduction technology in the coronavirus disease 2019 era and consequences on human reproductive system

COVID-19: A Challenge to the Safety of Assisted Reproduction

Potential effects of COVID-19 on reproductive systems and fertility; assisted reproductive technology guidelines and considerations: a review